Alexion Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) Tops Q2 EPS by 37c, Offers FY Guidance
July 26, 2018 6:36 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $2.07, $0.37 better than the analyst estimate of $1.70. Revenue for the quarter came in at $1.05 million versus the consensus estimate of $977.68 million.
GUIDANCE:
Alexion Pharma sees FY2018 EPS of $7.00-$7.15, versus the consensus of... More
